From $617 to $350: CVS sets a "break-even price" for weight-loss drugs, says drugmakers can still make money

An analysis of insurance claims data found that if GLP-1 drugs used for weight loss and diabetes were priced below US$350 per month, payerssuch as employers and plan sponsorswould achieve net savings from reduced use of related medical services. The analysis was conducted by CVS Health based on claims data for patients recently starting the drugs from its insurance subsidiary Aetna. Eli Lilly (LLY.US) sells Zepbound (tirzepatide) for obesity and Mounjaro (tirzepatide) for type 2 diabetes; Novo Nordisk A/S Sponsored ADR Class B (NVO.US) sells Wegovy (semaglutide, for weight loss) and Ozempic (semaglutide, for diabetes), respectively. Gap between current prices and the "break-even point" According to an October 2025 report from the Employee Benefit Research Institute (EBRI), employers and health plan sponsors pay an average of US$617 to US$766 per month for GLP-1 drugs. At that level, drug costs cannot be offset by savings from reduced use of medical services. Eli Lilly and Novo Nordisk A/S Sponsored ADR Class B currently offer GLP-1 prices to self-pay customers ranging from US$299 to US$499 per month (depending on dose)already close to, but not yet broadly below, the US$350 threshold. CVS Health Chief Medical Officer Amy Compton-Phillips told Reuters she believes drugmakers can still be profitable even if they sell at prices below US$350 per month. The analysis will be released on Sunday at the HLTH USA conference in Las Vegas. Why this analysis is worth noting For employers and insurance plans, the GLP-1 ledger has always been a dilemma: the drug cost alone is a huge expense, but if weight loss leads to fewer complications and reduced demand for hospitalization and surgery, long-term total costs may actually be lower. CVS's analysis effectively provides an actionable pricing coordinate for this debateUS$350/month. This statement also comes at a key moment for CVS itself: the company just announced last week that it will split into two companies in the first half of 2028, with Aetna and Caremark (PBM) remaining within CVS Health and the retail pharmacy operating independently. As a conglomerate that simultaneously controls insurance (Aetna), pharmacy benefit management (Caremark), and a pharmacy network, CVS's position on GLP-1 pricing naturally carries the implication of "buyer bargaining."